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Abstract
Background: Cervical cancer is the second most common cancer in women worldwide. Infection with certain
human papillomavirus (HPV) genotypes is the most important risk factor associated with cervical cancer. This study
analysed the distribution of type-specific HPV infection among women with normal and abnormal cytology, to
assess the potential benefit of prophylaxis with anti-HPV vaccines.
Methods: Cervical samples of 2,461 women (median age 34 years; range 15-75) from the centre of Spain were
tested for HPV DNA. These included 1,656 samples with normal cytology (NC), 336 with atypical squamous cells of
undetermined significance (ASCUS), 387 low-grade squamous intraepithelial lesions (LSILs), and 82 high-grade
squamous intraepithelial lesions (HSILs). HPV detection and genotyping were performed by PCR using 5’-
biotinylated MY09/11 consensus primers, and reverse dot blot hybridisation.
Results: HPV infection was detected in 1,062 women (43.2%). Out of these, 334 (31%) samples had normal
cytology and 728 (69%) showed some cytological abnormality: 284 (27%) ASCUS, 365 (34%) LSILs, and 79 (8%)
HSILs. The most common genotype found was HPV 16 (28%) with the following distribution: 21% in NC samples,
31% in ASCUS, 26% in LSILs, and 51% in HSILs. HPV 53 was the second most frequent (16%): 16% in NC, 16% in
ASCUS, 19% in LSILs, and 5% in HSILs. The third genotype was HPV 31 (12%): 10% in NC, 11% in ASCUS, 14% in
LSILs, and 11% in HSILs. Co-infections were found in 366 samples (34%). In 25%, 36%, 45% and 20% of samples
with NC, ASCUS, LSIL and HSIL, respectively, more than one genotype was found.
Conclusions: HPV 16 was the most frequent genotype in our area, followed by HPV 53 and 31, with a low
prevalence of HPV 18 even in HSILs. The frequency of genotypes 16, 52 and 58 increased significantly from ASCUS
to HSILs. Although a vaccine against HPV 16 and 18 could theoretically prevent approximately 50% of HSILs,
genotypes not covered by the vaccine are frequent in our population. Knowledge of the epidemiological
distribution is necessary to predict the effect of vaccines on incidence of infection and evaluate cross-protection
from current vaccines against infection with other types.
Background
The association of human papillomavirus (HPV) infection
with cervical cancer and its precursor lesions is well estab-
lished [1,2]. More than one hundred HPV genotypes have
been described, about 40 of which can infect mucosal
epithelia [3], causing mainly transient infections [4].
Based on the etiological role in the progression to cervi-
cal cancer, 15 HPV genotypes have demonstrated strong
oncogenic potential and are classified as high-risk HPVs
[5]. Persistent infection with oncogenic types of HPV is
considered the main risk factor associated with this disease.
The HPV genotypes and prevalence found in different
regions of the world vary both in type and incidence, prob-
ably as a consequence of the many factors associated with
HPV infection [6]. In a substantial percentage of HPV
infections, two or more genotypes may be found. About
20-50% of the infected women carry more than one viral
type [7,8]. For some groups, co-infection with multiple
HPV types correlates with the severity of cervical intrae-
pithelial neoplasia [9]. In contrast, other authors [10,11]
have reported that infection with multiple types does not
increase the risk of developing or progression of cervical
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any medium, provided the original work is properly cited.neoplasia. HPV typing has important prognostic and thera-
peutic value and the recent development of HPV vaccines
makes it increasingly more important. It has been sug-
gested that the impact of the vaccines could vary depend-
ing on the regional distribution of HPV types and co-
infection patterns. To investigate the potential impact of
vaccination strategy, it is essential to assess the local distri-
bution of HPV types and the incidence of co-infections.
The aim of the present study was to investigate the distri-
bution of HPV subtypes and its relationship with cervical
lesions in women in Madrid, Spain.
Methods
Specimen preparation
A total of 2,461 cytological specimens from May 2006 to
June 2010 were included in this study. Patients were
selected if both molecular analysis and cytology were avail-
able and if no previous HPV study had been performed.
Cytological samples corresponded to patients attending
the specialised gynaecology outpatient clinics of the Hos-
pital Universitario Puerta de Hierro, Madrid, Spain. These
patients were selected on the basis of a previous abnormal
Pap smear. A second sample was obtained, for which,
exfoliated cervical cells were obtained using a cytobrush
and collected in PreservCyt Solution (Cytyc Corporation,
Malborough, MA). The slides were prepared with a
TP2000 (Cytyc) instrument as recommended by the man-
ufacturer. ThinPrep cytological slides were screened and
the adequacy and the degree of abnormality were assessed
using the criteria set out in The Bethesda System 2001
guidelines http://www.asccp.org/ConsensusGuidelines/
2001BethesdaSystem/tabid/5969/Default.aspx. Residual
liquid material from ThinPrep samples was used for HPV
detection. One millilitre of each collected PreservCyt sam-
ple was aliquoted with an individual sterile pipette for
molecular study. DNA was extracted with QIacube DNA
Investigator Kit (Qiagen, Hilden, Germany) in accordance
with the manufacturer’s instructions.
HPV genotyping
HPV DNA detection and genotyping were performed by
PCR using the L1 consensus HPV PGMY09/PGMY11
primer set [12], and flow-through hybridisation (HybriBio
Limited, Hong Kong) as described previously [13,14]. It
generates an amplicon that is approximately 450 bp long
and appropriate for type identification. Positive and nega-
tive controls were used in each PCR. The gene chip con-
tained type-specific oligonucleotides immobilised on a
nylon membrane. The final results were detected by col-
orimetric changes on the chip under direct visualisation.
HPV types included in the kit were: high-risk genotypes:
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68;
low-risk: 6, 11, 42, 43 and 44; and probable high-risk: 53
and 81.
Statistical analysis
HPV genotype distribution analysis was performed using
SPSS version 15.0. The c
2 test was used to evaluate statisti-
cal significance between genotype, cytological lesion and
age. The median age of 33 years was chosen to dichotomise
age in the analysis of multiple genotypes infection. The
study protocol was approved by our institutional review
board and informed consent was obtained in each case.
Results
There were 2,461 samples from women aged 15-75 years
analysed for HPV infection from May 2006 to June 2010:
1,399 (56.8%) were negative for HPV and 1,062 (43.2%)
were positive. The cytological diagnosis was: 1,656 (67.3%)
with normal cytology (NC); 336 (13.7%) with atypical
squamous cell of undetermined significance (ASCUS); 387
(15.7%) low-grade squamous intraepithelial lesions
(LSILs); and 82 (3.3%) high-grade squamous intraepithelial
lesions (HSILs). The percentage of cases positive for HPV
infection in the different diagnostic categories was: 20% in
NC, 84% in ASCUS, 94% in LSILs, and 96% in HSILs
(Table 1).
The current analysis focused on the 1,062 HPV-posi-
tive samples to establish the distribution of HPV subtypes
in our area. Cytological diagnosis of these HPV-positive
samples included 334 (31%) from women with negative
cytology and 728 (69%) with some cytological abnormal-
ity. The cytological diagnosis of abnormal cases was as
follows: 284 cases (27%) with ASCUS, 365 (34%) with
LSILs, and 79 (8%) with HSILs.
Mean age of the patients was 34 ± 10.5 years (range 15-
75). Median age of NC patients was 34.5 years, 34.2 years
for ASCUS, 32.3 years for LSILs, and 39.6 years for
HSILs. The distribution of the cytological diagnoses with
regard to age is shown in Table 2. Women older than 32
years had the following cytological distribution: 33% NC,
25% ASCUS, 30% LSIL, and 12% HSIL, whereas in
women younger than 33 years, only 4% had HSILs, 39%
LSILs, 28% ASCUS and 29% NC.
The most common HPV types in the complete series
were as follows: 16 (28%), 53 (16%), 31 (12%), 52 (10%), 6
(9%), 18 (8%), 58 (8%), and 66 (8%). The prevalence of
other HPV types was: 33 (5%), 39 (5%), 56 (5%), 81 (5%),
42 (4%), 45 (4%), 11 (3%), and 51 (3%). The most common
Table 1 Association between cytological lesions and HPV
positivity
Lesion HPV
negative, n (%)
HPV
positive, n (%)
NC (n = 1656) 1322 (79.8%) 334 (20.2%)
ASCUS (n = 336) 52 (15.5%) 284 (84.5%)
LSIL (n = 387) 22 (5.7%) 365 (94.3%)
HSIL (n = 82) 3 (3.7%) 79 (96.3%)
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53 (16%), 6 (10%), 31 (10%) and 52 (8%). HPV18 was
found in 6% of NC cases. In abnormal samples, the distri-
bution was as follows (Table 3). ASCUS: 16 (31%), 53
(16%), 31 (11%), 52 (11%) and 6 (10%); LSILs: 16 (26%), 53
(19%), 31 (14%), 18 (11.5%), 52 (11%) and 66 (11%); and
HSILs: 16 (51%), 52 (14%), 31 (11%), 33 (10%) and 58
(8%). The three most frequent HPV types were 16, 53 and
31 in NC, ASCUS and LSILs, respectively.
Single infection (one HPV type) was observed in 696
(65.5%) samples, and 366 (34.5%) patients were infected
with multiple HPV types. Double infections (two different
genotypes) accounted for 60% of the multiple infections,
three genotypes were detected in 26% of these 366 samples,
and four or more types in 14%. In women under 33 years
old, infections due to more than one HPV type were found
in 39.6% of cases, whereas in those older than this, the pre-
valence was 26.7% (p < 0.01). HPV 16 was the most com-
mon genotype detected in co-infections, and was present
in 38% of cases, followed by HPV 53 (27%) and HPV 31
(20%). Co-infections were found in 25% of NC, 36% of
ASCUS, 45% of LSIL, and 20% of HSIL cases (Table 4).
Distribution of cytological lesions in those 366 samples was
as follows: 23% NC, 28% ASCUS, 45% LSIL, and 4% HSIL.
Single infection in HSIL samples was found in 80% of cases
(63 samples), and HPV 16 was detected in 50% of them.
Other genotypes found in HSIL single infection were HPV
3 1( 9 . 5 % ) ,H P V3 3( 7 . 9 % ) ,H P V5 2( 6 . 3 % ) ,a n dH P V5 8
(4.8%). HPV 18 as single infection in HSILs was found in
one case and in three cases as co-infection with HPV 52.
The global results demonstrated that HPV 16 was the
most prevalent infection (28%), whereas HPV 18 was
found more rarely (8%).
Discussion
Our specimens came from a group of women who
attended a cervical pathology unit because of a previous
abnormal Pap test result. We selected the HPV-positive
cases to investigate the genotype distribution in our area.
Several studies have been published concerning genotype
distribution in several Spanish regions [14-18], but few
data are available about the distribution in Madrid [19].
The prevalence and distribution of HPV genotypes varies
greatly worldwide, and these differences might be related
to the complex geographical and biological interplay
between different HPV types and host immunogenetic
factors [20].
Consistent with previously published data, genotype
HPV 16 was the most common type in our series, and
was detected in 28% of samples. With the exception of
Eastern Africa, China, Japan and Taiwan [21-23], HPV 16
is the most prevalent type in all parts of the world. Our
study showed that HPV 53 was the second most common
genotype (16% in the whole series), which is similar to
previous Italian [24,25] and Spanish [17,19,26] studies,
however, HPV 53 is not a frequent genotype in other
Mediterranean countries, such as Greece and Turkey
[27,28]. The epidemiological patterns of HPV type preva-
lence could differ depending on the region of origin.
Another factor that could influence the genotype distri-
bution is the primer system used. The GP5+/6+ primer
set is less sensitive for HPV 53 detection, whereas MY09/
MY11 is less sensitive for HPV 31 [29].
Nearly a third of HPV-positive samples in our series
were detected in patients with normal cytology. This pre-
valence is higher than that of other Spanish studies. This
Table 2 Distribution of cytological diagnosis in
HPV-positive samples with regard to age
Lesion ≥33 yrs
n = 499
< 33 yrs
n = 528
NC 33.3% 28.8%
ASCUS 25.5% 27.8%
LSIL 29.7% 39.6%
HSIL 11.5% 4.0%
c
2 = 30.22; p = 0.000
Table 3 Distribution of HPV genotypes found in each cytological diagnosis
6 11 16 18 31 33 39 42 45 51 52 53 56 58 66 81 Others
NC (n = 334) 10.2%
(34)
2.1%
(7)
21%
(70)
6.3%
(21)
10.5%
(35)
4.8%
(16)
5.4%
(18)
4.2%
(14)
3.6%
(12)
1.2%
(4)
8.4%
(28)
16.2%
(54)
2.4%
(8)
7.5%
(25)
6%
(20)
4.8%
(16)
15%
(50)
ASCUS (n = 284) 9.9%
(28)
3.9%
(11)
30.6%
(87)
7.7%
(22)
11.3%
(32)
4.2%
(12)
5.3%
(15)
3.2%
(9)
4.9%
(14)
1.1%
(3)
10.9%
(31)
15.8%
(45)
3.2%
(9)
7%
(20)
7%
(20)
6.3%
(18)
13%
(37)
LSIL (n = 365) 10.1%
(37)
3.8%
(14)
26.3%
(96)
11.5%
(42)
14.2%
(52)
3.8%
(14)
5.2%
(19)
7.1%
(26)
3.3%
(12)
8.5%
(31)
10.7%
(39)
18.9%
(69)
7.9%
(29)
10.1%
(37)
11.5%
(42)
5.2%
(19)
16.2%
(59)
HSIL (n = 79) 1.3%
(1)
0 50.6%
(40)
5.1%
(4)
11.4%
(9)
10.1%
(8)
1.3%
(1)
0 2.5%
(2)
1.3%
(1)
13.9%
(11)
5.1%
(4)
5.1%
(4)
7.6%
(6)
1.3%
(1)
3.8%
(3)
6.3%
(5)
Table 4 Correlation between HPV co-infection and
cytological lesions
Cytological lesion Mono-infection Co-infection
NC (n = 334) 251 (75.1%) 83 (24.9%)
ASCUS (n = 284) 183 (64.4%) 101 (35.6%)
LSIL (n = 365) 199 (54, 5%) 166 (45.5%)
HSIL (n = 79) 63 (79.7%) 16 (20.3%)
Total 696 (65.5%) 366 (34.5%)
c
2 = 40.49; p = 0.000
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an abnormal Pap test and attended a specialised gynaecol-
ogy unit for cervical pathology.
In NC samples, HPV 16 was the most common geno-
type (21%), followed by HPV 53 (16%). The HPV distribu-
tion found in NC cases is similar to that reported by
Conesa et al. [26] from a cohort of women from Eastern
Spain. The same distribution was found in ASCUS and
LSIL samples with HPV 16 (31% and 26%, respectively)
being the most prevalent, followed by HPV 53 (16% and
19%, respectively). The high prevalence of HPV 53 in
ASCUS and LSILs is similar to that in other studies from
Spain and France.
In HSILs, the most frequent type was HPV 16 (51%), fol-
lowed by 52 (14%) and 31 (11%). In our series, HPV 53
was not detected in HSILs, suggesting that it is not a high-
risk type. An interesting finding of our study was that
HPV 52 was the second most common genotype in HSIL
cases, whereas its prevalence in NC and LSILs was lower.
Recently, multiple HPV infections have been analysed
because, with the development of anti-HPV vaccines not
covering all genotypes, the distribution of infection with
types not covered by vaccines could be affected. The elimi-
nation of one HPV type could affect the natural history of
the remaining genotypes. Therefore, obtaining a solid
knowledge of genotype HPV distribution is becoming
imperative. Multiple types of HPV have been described in
up to 50% of NC and LSIL cases in the population in
Northwest Spain [15], in accordance with other studies
[30].
In the present study, multiple infections were detected
in 34% of samples, and were more frequent in younger
women (< 33 years). This observation is consistent with
the results of Mejlhede et al. [8], and supports the fact that
greater sexual activity in younger women may be asso-
ciated with the transmission of multiple HPV types. The
presence of co-infection was more frequent in LSIL cases
(45%), followed ASCUS (36%) and NC (25%), whereas a
decreased frequency of co-infection was found in HSILs
(20%). Similar to other Spanish studies [15,26], in our ser-
ies, ASCUS/LSILs were associated with co-infections,
whereas HSILs were associated with single infection (p <
0.01). It is still not clear whether co-infection with several
types increases the risk of progression. It seems that, as
lesions progress from low to high grade, high-risk onco-
genic types may persist, whereas less oncogenic types are
eliminated [26].
Conclusions
In conclusion, this study demonstrates an important
prevalence of high- and low-risk HPV genotypes even in
patients with no evidence of cytological anomalies, as
reported by Krambeck et al. [31]. We also demonstrated
a high incidence of HPV co-infection, mainly in LSILs.
It is important to detect the specific genotype for two
reasons: (1) to differentiate persistent and new infec-
tions; and (2) to increase our knowledge of the epide-
miological distribution because it is a necessary basis to
predict the effect of vaccines on the incidence of infec-
tion, and to evaluate the cross-protection from current
vaccines.
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